|
gptkbp:instanceOf
|
gptkb:antidepressant
gptkb:drug
gptkb:selective_serotonin_reuptake_inhibitor
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AB10
|
|
gptkbp:brand
|
gptkb:Lexapro
gptkb:Cipralex
|
|
gptkbp:CASNumber
|
128196-01-0
|
|
gptkbp:chemicalFormula
|
C20H21FN2O
|
|
gptkbp:contraindication
|
concomitant use with MAO inhibitors
|
|
gptkbp:developedBy
|
gptkb:Lundbeck
|
|
gptkbp:eliminationHalfLife
|
27-32 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1997
|
|
gptkbp:hasEnantiomer
|
gptkb:citalopram
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:NSAIDs
gptkb:triptans
gptkb:St._John's_Wort
lithium
other serotonergic drugs
|
|
gptkbp:IUPACName
|
(S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Lundbeck
gptkb:Forest_Laboratories
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:meltingPoint
|
146-149°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2012 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
56%
|
|
gptkbp:PubChem_CID
|
146570
DB01175
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:sexual_dysfunction
nausea
fatigue
insomnia
dry mouth
increased sweating
|
|
gptkbp:UNII
|
4ZWB8V8Y2T
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Escitalopram
|